Cibinqo

Chemical Nameabrocitinib
Dosage FormTablets (oral; 50 mg, 100 mg, 200 mg)
Drug ClassKinase inhibitors
SystemSkin
CompanyPfizer
Approval Year2022

Indication

  • For the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable
Last updated on 5/18/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cibinqo (abrocitinib) Prescribing Information.2022Pfizer Labs, New York, NY